Oct 8, 2026 · 25 min · 7 segments
We love to hear from our listeners. Send us a message. On episode 139, Host Erin Harris talks to Jonathan Rigby, President and CEO of Sernova (and…
Will RustGuestErin HarrisHost
Jonathan RigbyGuestThank you so much for your time, and I'm looking very forward to our conversation today.
So tell us a little bit about the relationship between Sernova, Siraxis, and then ultimately what will be known as BetaNova.
There's big news, and it's very exciting, but we'd love to hear it from-- directly from, from you.
So look, uh, we, um, the, the folks at Sernova and the folks at Siraxis, we share, uh, the same mission, and the mission is to create what essentially would be a functional cure for people with type 1 diabetes.
Uh, myself and my team are highly motivated on this, and, uh, I've been living with type 1 diabetes all my life, so this is a, a very personal thing for me.
And, uh, uh, in a nutshell, so, you know, Sernova, we've developed this implantable retrieval, retrievable, uh, medical device called the Cell Pouch, which can be put underneath the skin of the abdomen, and it can house islet cells, which are the cells that create insulin and other hormones to control, uh, blood glucose.
And, uh, we finished a phase one, two clinical trial, uh, using cadaveric islets, where we met all the primary and the secondary endpoints.
So then the other thing that we need in the future is a sustainable, scalable supply of islet cells that will be manufactured under a GMP facility, uh, so that we can scale this up and take this commercial, and that's what Siraxis bring to the table.
So, uh, Will can tell you in a little bit about the, the two cell types that we have.
But basically by combining these two technologies and, uh, working through some strategic decisions we have about immune regulation, immune system regulation, uh, we create what we call a functional biohybrid organ, uh, to bring a clinical trial, uh, early in the new year to eventually get to a functional cure for this terrible disease.
Thank you so much for your time, and I'm looking very forward to our conversation today.
So tell us a little bit about the relationship between Sernova, Siraxis, and then ultimately what will be known as BetaNova.
There's big news, and it's very exciting, but we'd love to hear it from-- directly from, from you.
So look, uh, we, um, the, the folks at Sernova and the folks at Siraxis, we share, uh, the same mission, and the mission is to create what essentially would be a functional cure for people with type 1 diabetes.
Uh, myself and my team are highly motivated on this, and, uh, I've been living with type 1 diabetes all my life, so this is a, a very personal thing for me.
And, uh, uh, in a nutshell, so, you know, Sernova, we've developed this implantable retrieval, retrievable, uh, medical device called the Cell Pouch, which can be put underneath the skin of the abdomen, and it can house islet cells, which are the cells that create insulin and other hormones to control, uh, blood glucose.
And, uh, we finished a phase one, two clinical trial, uh, using cadaveric islets, where we met all the primary and the secondary endpoints.
So then the other thing that we need in the future is a sustainable, scalable supply of islet cells that will be manufactured under a GMP facility, uh, so that we can scale this up and take this commercial, and that's what Siraxis bring to the table.
So, uh, Will can tell you in a little bit about the, the two cell types that we have.
But basically by combining these two technologies and, uh, working through some strategic decisions we have about immune regulation, immune system regulation, uh, we create what we call a functional biohybrid organ, uh, to bring a clinical trial, uh, early in the new year to eventually get to a functional cure for this terrible disease.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
